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The field of clinical microbiology comprises both 
diagnostic microbiology, the identification of patho­
gens from clinical samples to guide management 
and treatment strategies for patients with infection, and 
public health microbiology, the surveillance and moni­
toring of infectious disease outbreaks in the community. 
Traditional diagnostic techniques in the microbiology 
laboratory include growth and isolation of micro­
organisms in culture, detection of pathogen­ specific 
anti bodies (serology) or antigens and molecular identi­
fication of microbial nucleic acids (DNA or RNA), most 
commonly via PCR. While most molecular assays target 
only a limited number of pathogens using specific prim­
ers or probes, metagenomic approaches characterize all 
DNA or RNA present in a sample, enabling analysis of 
the entire microbiome as well as the human host genome 
or transcriptome in patient samples. Metagenomic 
approaches have been applied for decades to charac­
terize various niches, ranging from marine environ­
ments1 to toxic soils2 to arthropod disease vectors3,4 to 
the human microbiome5,6. These tools have also been 
used to identify infections in ancient remains7, discover 
novel viral pathogens8 and characterize the human 
virome in both healthy and diseased states9–11 and for 
forensic applications12.
The capacity to detect all potential pathogens — 
bacteria, viruses, fungi and parasites — in a sample and 
simultaneously interrogate host responses has great 
potential utility in the diagnosis of infectious disease. 
Metagenomics for clinical applications derives its roots 
from the use of microarrays in the early 2000s13,14. Some 
early successes using this technology include the discov­
ery of the SARS coronavirus15, gene profiling of muta­
tions in cancer16 and in­ depth microbiome analysis of 
different sites in the human body17. However, it was the 
advent of next­ generation sequencing (NGS) techno­
logies in 2005 that jump­ started the metagenomics 
field18. For the first time, millions to billions of reads 
could be generated in a single run, permitting analysis of 
the entire genetic content of a clinical or environmental 
sample. The proliferation of available sequencing instru­
ments and exponential decreases in sequencing costs 
over the ensuing decade drove the rapid adoption of 
NGS technology.
To date, several studies have provided a glimpse into 
the promise of NGS in clinical and public health settings. 
For example, NGS was used for the clinical diagnosis 
of neuroleptospirosis in a 14­year­ old critically ill boy 
with meningoencephalitis19; this case was the first to 
demonstrate the utility of metagenomic NGS (mNGS) in 
providing clinically actionable information, as success­
ful diagnosis prompted appropriate targeted antibiotic 
treatment and eventual recovery of the patient. Examples 
in public health microbiology include the use of NGS, in 
combination with transmission network analysis20, to 
investigate outbreaks of the Escherichia coli strain 
O104:H4 (ref.21) and for surveillance of antimicrobial 
resistance in the food supply by bacterial whole­ genome 
sequencing22. Increasingly, big data provided by mNGS 
is being leveraged for clinical purposes, including charac­
terization of antibiotic resistance directly from clinical 
samples23 and analysis of human host response (tran­
scriptomic) data to predict causes of infection and evalu­
ate disease risk24,25. Thus, mNGS can be a key driver for 
precision diagnosis of infectious diseases, advancing 
precision medicine efforts to personalize patient care in 
this field.
Despite the potential and recent successes of 
metagenomics, clinical diagnostic applications have 
lagged behind research advances owing to a number 
of factors. A complex interplay of microbial and host 
factors influences human health, as exemplified by the 
role of the microbiome in modulating host immune 
responses26, and it is often unclear whether a detected 
microorganism is a contaminant, colonizer or bona fide 
pathogen. Additionally, universal reference standards 
Microbiome
The entirety of organisms that 
colonize individual sites in the 
human body.
Microarrays
Commonly referred to as 
‘chips’, these platforms consist 
of spots of DNA fragments, 
antibodies or proteins printed 
onto surfaces, enabling massive 
multiplexing of hundreds to 
thousands of targets.
Reads
In DNA sequencing, reads are 
inferred sequences of base 
pairs corresponding to part of 
or all of a single DNA fragment.
Metagenomic NGS
(mNGS). A shotgun sequencing 
approach in which all genomic 
content (DNA and/or rNA)  
of a clinical or environmental 
sample is sequenced.
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and proven approaches to demonstrate test valida­
tion, reproducibility and quality assurance for clinical 
metagenomic assays are lacking. Considerations of cost, 
reimbursement, turnaround time, regulatory considera­
tions and, perhaps most importantly, clinical utility also 
remain major hurdles for the routine implementation 
of clinical mNGS in patient care settings27.
We review here the various applications of mNGS 
currently being exploited in clinical and public health 
settings. We discuss the challenges involved in the 
adoption of mNGS in the clinical laboratory, including 
validation and regulatory considerations that extend 
beyond its initial development in research laboratories, 
and propose steps to overcome these challenges. Finally, 
we envisage future directions for the field of clinical 
metagenomics and anticipate what will be achievable in 
the next 5 years.
Applications of clinical metagenomics
To date, applications of clinical metagenomics have 
included infectious disease diagnostics for a variety of 
syndromes and sample types, microbiome analyses in 
both diseased and healthy states, characterization of the 
human host response to infection by transcriptomics 
and the identification of tumour­ associated viruses and 
their genomic integration sites (fIG. 1; TAble 1). Aside 
from infectious disease diagnostics, adoption of mNGS 
in clinical laboratories has been slow, and most applica­
tions have yet to be incorporated into routine clinical 
practice. Nonetheless, the breadth and potential clini­
cal utility of these applications are likely to transform 
the field of diagnostic microbiology in the near future.
Infectious disease diagnosis
The traditional clinical paradigm for diagnosis of infec­
tious disease in patients, applied for more than a century, 
involves a physician formulating a differential diagnosis 
and then ordering a series of tests (generally ‘one bug, 
one test’) in an attempt to identify the causative agent. 
The spectrum of conventional testing for pathogens 
in clinical samples ranges from the identification of 
microorganisms growing in culture (for example, by 
biochemical phenotype testing or matrix­ assisted laser 
desorption/ionization (MALDI) time­ of­flight mass 
spectrometry), the detection of organism­ specific bio­
markers (such as antigen testing by latex agglutination 
or antibody testing by enzyme­ linked immunosorbent 
assay (ELISA)) or nucleic acid testing by PCR for sin­
gle agents to multiplexed PCR testing using syndromic 
panels. These panels generally include the most common 
pathogens associated with a defined clinical syndrome, 
such as meningitis and encephalitis, acute respiratory 
infection, sepsis or diarrhoeal disease28–31.
Molecular diagnostic assays provide a fairly cost­ 
effective and rapid (generally <2 hours of turnaround 
time) means to diagnose the most common infections. 
However, nearly all conventional microbiological tests in 
current use detect only one or a limited panel of patho­
gens at a time or require that a microorganism be suc­
cessfully cultured from a clinical sample. By contrast, 
while NGS assays in current use cannot compare with 
conventional tests with respect to speed — the sequenc­
ing run alone on a standard Illumina instrument takes 
>18 hours — mNGS enables a broad range of pathogens 
— viruses, bacteria, fungi and/or parasites — to be 
identified from culture or directly from clinical samples 
on the basis of uniquely identifiable DNA and/or RNA 
sequences32. Another key advantage of NGS approaches 
is that the sequencing data can potentially be leveraged 
for additional analyses beyond the mere identification 
of a causative pathogen, such as microbiome character­
ization and parallel analyses of human host responses 
through transcriptome profiling by RNA sequencing 
(RNA­ seq). Thus, the clinical utility of NGS in diagno­
sis may be in the most difficult­ to­diagnose cases or for 
immunocompromised patients, in whom the spectrum 
of potential pathogens is greater. Eventually, mNGS 
may become cost competitive with multiplexed assays 
or used as an upfront ‘rule out’ assay to exclude infec­
tious aetiologies. Of course, detection of nucleic acids, 
either by multiplex PCR panels or NGS, does not by itself 
prove that an identified microorganism is the cause of 
the illness, and findings have to be interpreted in the 
clinical context. In particular, discovery of an atypical 
or novel infectious agent in clinical samples should be 
Fig. 1 | Clinical applications of metagenomic sequencing. A | Applications in infectious 
disease diagnostics include direct identification of microorganisms from primary clinical 
samples (part Aa); antimicrobial resistance prediction by characterization of resistance 
genes (part Ab); detection of species- level or strain- level virulence determinants, such as 
secretion of specific endotoxins or exotoxins (part Ac); and antiviral resistance prediction 
(part Ad). As shown for HIV-1, recovery of the complete viral genome from a patient 
sample by metagenomic next- generation sequencing (mNGS) (part Ad, graph) facilitates 
sequence analysis to predict susceptibility or resistance to antiretroviral drugs (part Ad, 
bar plot); the susceptibility profile for the analysed strain (black bars) predicts resistance  
to the non- nucleoside reverse transcriptase inhibitor (NNRTI) class of drugs (denoted by 
an asterisk), as opposed to nucleoside reverse transcriptase inhibitors (NRTIs) or protease 
inhibitors (PIs). B | Microbiome analyses can inform disease prognosis in acute and chronic 
disease states and underlie the development of probiotic therapies. Coloured bars 
represent individual microbiota species. A reduction in species diversity is seen in 
dysbiosis (an unhealthy state), such as present in patients with Clostridium difficile- 
associated disease. Stool from healthy individuals can be harvested to treat patients with 
C. difficile infection by faecal stool transplantation or as orally administered encapsulated 
faecal pills. Alternatively , synthetic stool generated from microbiota species observed in 
healthy individuals can be used as probiotics to treat patients. In addition to C. difficile 
infection, chronic diseases such as obesity , inflammatory bowel disease and diabetes 
mellitus are potential targets for probiotic therapy. C | RNA- sequencing-based 
transcriptomics can improve the diagnosis of infectious and non- infectious conditions  
on the basis of the human host response. Host transcriptomic profiling by NGS can enable  
the construction of a classifier metric to discriminate between patients with infection  
(red bars) from uninfected patients (blue bars) with high accuracy (part Ca). Metric scores 
above the dotted line indicate infection, whereas scores below the dotted line indicate 
absence of infection; the overall accuracy of the classifier metric shown is 83%. Cluster 
heat map analysis identifies individual, differentially expressed host genes associated  
with infection (genes A–F) versus those associated with no infection (genes G–L) (part Cb). 
D | Sequencing of viral tumours or liquid biopsy analyses in oncology can be used for 
simultaneous pathogen detection and characterization of host genetic mutations.  
mNGS can be used to detect Merkel cell polyomavirus, the virus associated with the 
development of Merkel cell carcinoma. Simultaneous sequencing of host DNA can 
identify mutations that arise from integration of the viral genome containing the  
full- length large T antigen (LT) followed by subsequent truncation of the LT antigen 
(part Da) or truncation of the LT antigen before viral genome integration (part Db). 
Both of these two mutations lead to cellular transformation that drives tumour 
proliferation. Although promising, many of these sequencing- based applications 
have yet to be incorporated into routine clinical practice. Part C is adapted from ref.25, 
CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by- nc-nd/4.0/). Part D is 
adapted from ref.134, CC BY 3.0 (https://creativecommons.org/licenses/by/3.0/).
Transmission network 
analysis
The integration of 
epidemiological, laboratory 
and genomic data to track 
patterns of transmission and  
to infer origin and dates of 
infection during an outbreak.
Precision medicine
An approach to medical care by 
which disease treatment and 
prevention take into account 
genetic information obtained 
by genomic or molecular 
profiling of clinical samples.
Reference standards
In laboratory test development, 
well- characterized, standardized 
and validated reference 
materials or databases that 
enable measurement of 
performance characteristics of 
an assay, including sensitivity, 
specificity and accuracy.
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followed up with confirmatory investigations such as 
orthogonal testing of tissue biopsy samples and demon­
stration of seroconversion or via the use of cell culture 
or animal models, as appropriate8, to ascertain its true 
pathogenic potential.
NGS of clinical samples as performed in either 
research or clinical laboratories involves a number of 
steps, including nucleic acid extraction, enrichment 
for DNA and/or RNA, library preparation, PCR ampli­
fication (if needed), sequencing and bioinformat­
ics analysis (fIG. 2). Any body fluid or tissue yielding 
sufficient nucleic acid is amenable to NGS analysis, 
which can either be targeted, that is, enriching indi­
vidual genes or genomic regions, or untargeted, as is 
the case for metagenomic ‘shotgun’ approaches (fIG. 2). 
The details for the specific steps vary by laboratory and 
are described extensively elsewhere33–37.
Targeted NGS analyses. Targeted approaches have 
the benefit of increasing the number and proportion 
of pathogen reads in the sequence data. This step can 
increase the detection sensitivity for microorganisms 
being targeted, although it limits the breadth of poten­
tial pathogens that can be identified. An example of a 
targeted approach is the use of highly conserved prim­
ers for universal PCR amplification and detection of all 
microorganisms corresponding to a specific type from 
clinical samples, such as 16S ribosomal RNA (rRNA) 
gene amplification for bacteria38,39 and 18S rRNA and 
internal transcribed spacer (ITS) gene amplification for 
Table 1 | Clinical microbiology approaches using next- generation sequencing
Sequencing method Clinical sample type Potential clinical indications Clinical test 
available?
Refs
Infectious disease diagnosis — targeted analyses
Amplicon sequencing (universal 
bacterial, fungal or parasitic rRNA 
sequencing)
Multiple body fluids and tissues Multiplexed pathogen detection Yesa 39
Amplicon sequencing (multiplexed 
primer panels)
Multiple body fluids and tissues Multiplexed pathogen detection No 135
Capture probe enrichment Multiple body fluids and tissues Viral genome recovery for infection 
control, epidemiology and public health
No 43,44,46,47
Capture probe enrichment Multiple body fluids and tissues Multiplexed pathogen detection No 49–52
Capture probe enrichment Multiple body fluids and tissues Antibiotic resistance characterization No 23,136
Infectious disease diagnosis — untargeted analyses
Metagenomic sequencing Blood (plasma) Culture- negative sepsis, endocarditis, 
febrile neutropenia, fever of 
unknown origin or monitoring of 
immunocompromised patients
Yesb 33,57
Metagenomic sequencing Respiratory secretions Culture- negative and/or PCR- negative 
pneumonia
Yesc 25,37,58,137,138
Metagenomic sequencing Cerebrospinal fluid Undiagnosed meningitis, encephalitis 
or myelitis
Yesd 36,37
Metagenomic sequencing Stool Severe diarrhoea No 139
Metagenomic sequencing Infected tissue or other body fluid Culture- negative infection No 118,140
Microbiome analyses
Metagenomic sequencing Stool Consumer- based microbiome testinge Noe No reference
Metagenomic sequencing Stool Guiding management and treatment  
of Clostridium difficile infection
No 141
Metagenomic sequencing Stool Chronic illnesses No 64
Metagenomic sequencing Respiratory secretions Aiding in diagnosis of acute respiratory 
infection
No 137
Human host response analyses
RNA sequencing Multiple sample types; whole 
blood or PBMC most common
Aiding diagnosis or characterization  
of infections such as bacterial sepsis  
or pneumonia; disease prognosis
No 24,25,68
Oncological analyses
Whole- genome tumour 
sequencing
Tumour Identification of viruses associated  
with cancer
No 142
Liquid biopsy sequencing Cell- free body fluids Simultaneous cancer and infectious 
disease testing
No 57,143
PBMC, peripheral blood mononuclear cell; rRNA , ribosomal RNA. aUniversity of Washington39, Fry Laboratories. bKarius33. cIDbyDNA37. dUniversity of California, 
San Francisco36. euBiome; testing is not for diagnosis or treatment of disease.
Latex agglutination
A clinical laboratory test for 
detection of a specific antibody 
in which the corresponding 
antigen is adsorbed on spherical 
polystyrene latex particles that 
undergo agglutination in the 
presence of the antibody.
Seroconversion
The development of detectable 
antibodies in the blood that are 
directed against an infectious 
agent, such as HIV-1, after 
which the infectious disease 
can be detected by serological 
testing for the antibody.
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fungi40 (fIG. 2). Previously, such approaches were followed 
by Sanger sequencing of the resulting PCR amplicon to 
identify the pathogen and make a diagnosis; now, this 
step is commonly accomplished using NGS. Universal 
PCR for detection of bacteria and fungi has now been 
adopted in many hospital laboratories and has increased 
the number and proportion of infectious diagnoses39,41, 
although the technique is limited by the breadth of 
detection (that is, bacteria or fungi only or even a more 
limited range of targets, such as mycobacteria only, 
depending on the primer sets used) and by concerns 
regarding sensitivity42.
Another example of a targeted NGS approach is the 
design of primers tiled across the genome to facilitate 
PCR amplification and amplicon NGS for recovery 
of viral genomes directly from clinical samples43. This 
method has been used to track the evolution and spread 
of Zika virus (ZIKV) in the Americas44–46 and of Ebola 
virus in West Africa47, with some demonstrations of 
real­ time monitoring having an impact on public health 
interventions.
Another targeted approach is capture probe enrich­
ment, whereby metagenomic libraries are subjected 
to hybridization using capture ‘bait’ probes48. These 
probes are generally 30–120 bp in length, and the num­
ber of probes can vary from less than 50 to more than 
2 million49–52. Although this enrichment method has been 
shown to increase the sensitivity of metagenomic detec­
tion in research settings, especially for viruses, it has yet to 
be used routinely for clinical diagnosis. A promising appli­
cation of this approach may be the enrichment of clinical 
samples for characterization of antibiotic resistance23, a 
considerable problem in hospitals and the primary focus 
of the US National Action Plan for Combating Antibiotic­ 
Resistant Bacteria53. However, drawbacks of capture probe 
enrichment, compared with untargeted approaches for 
infectious disease diagnosis, include a bias towards tar­
geted microorganisms, added steps, increased costs and 
long hybridization times (24–48 hours) as a result of the 
additional processing needed for maximal efficiency.
Untargeted metagenomic NGS analyses. Untargeted 
shotgun mNGS analyses forego the use of specific 
primers or probes54. Instead, the entirety of the DNA 
and/or RNA (after reverse transcription to cDNA) 
is sequenced. With pure cultures of bacteria or fungi, 
mNGS reads can be assembled into partial or complete 
genomes. These genome sequences are then used for 
subtyping and/or monitoring hospital outbreaks in sup­
port of infection control and/or public health surveil­
lance efforts. For example, a seminal study described the 
use of whole­ genome sequencing of multidrug­ resistant, 
carbapenemase­ producing Klebsiella pneumoniae to 
track the origin and evolution of a hospital outbreak55. 
This study demonstrated for the first time the high­ 
resolution mapping of likely transmission events in a 
hospital, some of which were unexpected on the basis 
of initial epidemiological data, and also identified puta­
tive resistance mutations in emerging resistant strains. 
The integration of genomic and epidemiological data 
yielded actionable insights that would have been useful 
for curbing transmission.
Untargeted mNGS of clinical samples is perhaps 
the most promising approach for the comprehensive 
diagnosis of infections. In principle, nearly all patho­
gens, including viruses, bacteria, fungi and parasites, 
can be identified in a single assay56. mNGS is a needle­ 
in­a­ haystack endeavour, as only a small proportion 
(typically <1%) of reads are non­ human, of which 
only a subset may correspond to potential pathogens. 
A limitation of mNGS is that the sensitivity of the 
approach is critically dependent on the level of back­
ground. Tissues, for example, have increased human 
host background relative to cell­ free body fluids, result­
ing in a reduced number and proportion of microbial 
reads and hence a decrease in mNGS sensitivity33,36,37. 
Moreover, defining specific microbial profiles that are 
diagnostic or predictive of disease development can be 
difficult, especially from nonsterile sites that harbour 
a complex microbiome, such as respiratory secretions 
or stool6. Nevertheless, several groups have successfully 
validated mNGS in Clinical Laboratory Improvement 
Amendments (CLIA)­certified clinical laboratories for 
the diagnosis of infections, including meningitis or 
encephalitis36,37, sepsis33,57 and pneumonia58, and these 
assays are now available for clinical reference testing 
of patients.
Clinical microbiome analyses
Many researchers now use mNGS instead of targeted 
sequencing of the 16S rRNA gene for in­ depth charac­
terization of the microbiome59. There is growing public 
awareness of the microbiome and its likely involvement 
in both acute and chronic disease states60. However, no 
microbiome­ based tests have been clinically validated 
for the diagnosis or treatment of disease, in part owing 
to an incomplete understanding of the complexity of the 
microbiome and its role in disease pathogenesis.
One future clinical application of microbiome 
analysis may be in the management and treatment of 
Clostridium difficile­ associated disease. C. difficile is an 
opportunistic bacterium that can infect the gut, result­
ing in the production of toxins that can cause diarrhoea, 
dehydration, sepsis and death. C. difficile infection occurs 
only in the setting of a microbiome that is altered by 
factors such as exposure to broad­ spectrum anti biotics 
or recent gastrointestinal surgery61. The importance of 
the microbiome in C. difficile infection is underscored 
by the 80–90% effectiveness of faecal stool transplan­
tation in treating and potentially curing the disease62,63. 
The use of mNGS to characterize the microbiome in 
multiple studies has facilitated the development of bac­
terial probiotic mixtures that can be administered as pills 
for prophylaxis or treatment of C. difficile­ associated 
disease (fIG. 1b).
Another potential application of the microbiome is 
in the analysis of bacterial diversity, which can provide 
clues as to whether a patient’s illness is infectious or 
non­ infectious. For example, a study of mNGS for the 
identification of respiratory pathogens in patients with 
pneumonia found that individuals with culture­ proven 
infection had significantly less diversity in their res­
piratory microbiome25. Alterations of the microbiome, 
known as dysbiosis, have also been shown to be related 
Library
In DNA sequencing, a 
collection of DNA fragments 
with known adapter sequences 
at one or both ends that is 
derived from a single clinical  
or environmental sample.
Sanger sequencing
A classical method of DNA 
sequencing based on selective 
incorporation of chain- 
terminating dideoxynucleotides 
developed by frederick Sanger 
and colleagues in 1977;  
now largely supplanted by 
next- generation sequencing.
Subtyping
In microbiology, refers to the 
identification of a specific 
genetic variant or strain of a 
microorganism (for example, 
virus, bacterium or fungus), 
usually by sequencing all  
or part of the genome.
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to obesity, diabetes mellitus and inflammatory bowel 
disease64, and manipulation of the microbiome may be 
a pathway to treating these pathological conditions.
Human host response analyses
Clinical mNGS typically focuses on microbial reads; 
however, there is a complementary role for the analysis 
of gene expression in studying human host responses to 
infection65 (fIG. 1C). mNGS of RNA libraries used for the 
detection of pathogens such as RNA viruses in clinical 
samples incidentally produces host gene expression data 
for transcriptome (RNA­ seq) analyses66. Although RNA­ 
seq analyses are commonly performed on whole blood 
or peripheral blood mononuclear cell (PBMC) samples, 
any body fluid or tissue type is potentially amenable 
to these analyses. Classification of genes by expression 
profiling using RNA­ seq has been used to characterize 
several infections, including staphylococcal bacterae­
mia67, Lyme disease68, candidiasis69, tuberculosis (dis­
criminating between latent and active disease risk)70–72 
and influenza73–75. Machine­ learning­based analyses 
of RNA­ seq data have been used for cancer classifi­
cation76, and translation of these approaches may be 
promising for infectious diseases. Panels containing a 
limited number of host biomarkers are being developed 
as diagnostic assays for influenza77, tuberculosis70 and 
bacterial sepsis78.
Although no RNA­ seq­based assay has been clinically 
validated to date for use in patients, the potential clin­
ical impact of RNA­ seq analyses is high. Interrogation 
of RNA reads from microorganisms corresponding to 
active microbial gene expression might enable the dis­
crimination between infection versus colonization25 and 
live (viable) versus dead organisms79. Moreover, RNA­ 
seq analyses of the human host can be used to identify 
novel or underappreciated host–microbial interactions 
directly from clinical samples, as previously shown for 
patients with Lyme disease68, dengue80 or malaria81. 
RNA­ seq may be particularly useful in clinical cases in 
which the causative pathogen is only transiently present 
(such as early Lyme disease82 or arboviral infections, 
including West Nile virus83 or ZIKV84); analogous to 
serologic testing, indirect diagnosis of infections may be 
possible on the basis of a pathogen­ specific human host 
response. Analysis of pathogen­ specific host responses 
may also be useful in discriminating the bona fide 
causative pathogen or pathogens in a complex clinical 
metagenomic sample, such as a polymicrobial abscess 
or respiratory fluid25. Yet another promising applica­
tion of RNA­ seq is in discriminating infectious versus 
non­ infectious causes of acute illness25. If an illness is 
judged more likely to be non­ infectious (for example, an 
autoimmune disease) on the basis of the host response, 
for example, clinicians may be more willing to discon­
tinue antibiotics and treat the patient aggressively with 
steroids and other immunosuppressive medications. 
As large­ scale sequencing data continue to be gener­
ated, perhaps driven by routine clinical mNGS testing, 
secondary mining of human reads might improve the 
accuracy of clinical diagnoses by incorporating both 
microbial and host gene expression data.
Applications in oncology
In oncology, whole­ genome or directed NGS approaches 
to identify mutated genes can be used to simultaneously 
uncover viruses associated with cancer (that is, herpes­
viruses, papillomaviruses and polyomaviruses) and/or 
to gather data on virus–host interactions85. For exam­
ple, mNGS was critical in the discovery of Merkel cell 
polyomavirus (fIG. 1D), now believed to be the cause 
of Merkel cell carcinoma, a rare skin cancer seen most 
commonly in elderly patients86. To date, the US Food and 
Drug Administration (FDA) has approved the clinical 
use of two NGS panels testing for actionable genomic 
aberrations in tumour samples87. Detection of reads cor­
responding to both integrated and exogenous viruses in 
these samples would be possible with the addition of 
specific viral probes to the panel or accomplished inci­
dentally while sequencing the whole tumour genome 
or exome.
Additional knowledge of integrated or active viral 
infections in cancers and their involvement in signal­
ling pathways may inform preventive and therapeutic 
interventions with targeted antiviral and/or chemothera­
peutic drugs88, as evidenced by the decreased risk of 
hepatitis C virus­ associated hepatocellular carcinoma 
after treatment with direct­ acting antiviral agents89. 
In the future, mNGS of cell­ free DNA from liquid biopsy 
samples (for example, plasma) might be leveraged for the 
simultaneous identification of early cancer and diagnosis 
of infection in immunocompromised patients (box 1).
Clinical implementation of metagenomic NGS
Implementation of mNGS in the clinical laboratory is 
a complex endeavour that requires customization of 
research protocols using a quality management approach 
consistent with regulatory standards90. Library prepara­
tion reagents, sequencing instrumentation and bioin­
formatics tools are constantly changing in the research 
environment. However, in the clinical laboratory, assays 
need to be implemented following standardized (locked­ 
down) protocols. Changes made to any component of the 
Liquid biopsy
The detection of molecular 
biomarkers from minimally 
invasive sampling of clinical 
body fluids, such as DNA 
sequences in blood, for the 
purpose of diagnosing disease.
Fig. 2 | Targeted versus untargeted shotgun metagenomic next- generation 
sequencing approaches. A variety of patient samples, as well as cultured microbial 
colonies, can be analysed using targeted or untargeted metagenomic next- generation 
sequencing (mNGS) methods for pathogen identification, microbiome analyses and/or 
host transcriptome profiling. Universal PCR (left) is a targeted mNGS approach that  
uses primers designed from conserved regions such as the ribosomal RNA (rRNA) genes 
that are universally conserved among bacteria (16S or 23S rRNA) or fungi and parasites 
(18S rRNA , 28S rRNA or internal transcribed spacer (ITS)). Other sets of primers can be 
designed to target a defined set of pathogens and/or genes and used for multiplex 
reverse transcription PCR or PCR (multiplexed amplicon PCR). NGS library preparation 
and sequencing of the resultant amplicons enable pathogen identification down to the 
genus or species level. Metagenomic sequencing (right) entails unbiased shotgun 
sequencing of all microbial and host nucleic acids present in a clinical sample. 
Separate DNA and RNA libraries are constructed; the DNA library is used for identification 
of bacteria, fungi, DNA viruses and parasites, whereas the RNA library is used for 
identification of RNA viruses and RNA sequencing- based human host transcriptome 
profiling (heat map, bottom right). As no primers or probes are used in unbiased mNGS, 
the vast majority of reads corresponds to the human host and, thus, detection of 
pathogens from metagenomic libraries is a ‘needle- in-a- haystack’ endeavour. An optional 
capture probe enrichment step using magnetic beads enables targeted mNGS of 
pathogens and/or genes from metagenomic libraries. All these methods are compatible 
with sequencing on traditional benchtop instruments such as the Illumina HiSeq and 
portable nanopore sequencers such as the Oxford Nanopore Technologies MinION.
◀
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assay need to be validated and shown to have acceptable 
performance before testing in patients. Periodic updates 
and repeat validation studies are performed as deemed 
necessary to incorporate interim technological advances 
in NGS reagents, protocols and instrumentation.
Metagenomic methods for pathogen detection pres­
ent a particularly challenging scenario for clinical vali­
dation (fIG. 3), as it is not practical to test an essentially 
unlimited number of different organisms for the assay 
to be considered validated. Although the FDA has pro­
vided general guidelines for clinical validation of NGS 
infectious disease testing91, there are no definitive reco­
mmendations for the clinical implementation of mNGS 
testing, nor is there mention of specific requirements. 
However, a best­ practice approach can be taken that 
includes failure­ mode analysis and evaluations of per­
formance characteristics using representative organ­
isms with ongoing assay monitoring and independent 
confirmation of unexpected results.
Sensitivity and enrichment or depletion methods
A key limitation of mNGS is its decreased sensitivity with 
high background, either predominantly from the human 
host (for example, in tissue biopsies) or the microbiome 
(for example, in stool). The background can be clini­
cally relevant as the pathogen load in infections, such as 
Shigella flexneri in stool from patients with diarrhoea92 or 
ZIKV in plasma from patients with vector­ borne febrile 
illness93, can be very low (<103 copies per ml).
Host depletion methods for RNA libraries have been 
developed and shown to be effective, including DNase I 
treatment after extraction to remove residual human 
background DNA94; the use of RNA probes followed 
by RNase H treatment95; antibodies against human and 
mitochondrial rRNA (the most abundant host RNA 
types in clinical samples)96; and/or CRISPR–Cas9­based 
approaches, such as depletion of abundant sequences by 
hybridization97.
Unfortunately, there are no comparably effective 
parallel methods for DNA libraries. Limited enrich­
ment in the 3–5 times range can be achieved with 
the use of antibodies against methylated human host 
DNA98, which enriches microbial reads owing to the 
lack of methylated DNA in most pathogen genomes. 
Differential lysis of human cells followed by degrada­
tion of background DNA with DNase I — thus retain­
ing and enriching for nucleic acid from organisms with 
cell walls, which include some bacteria and fungi — has 
been shown to provide substantial microbial enrichment 
of up to 1,000 times94,99,100. However, the performance of 
differential lysis methods can be limited by a number 
of factors. These limitations include potential decreased 
sensitivity for microorganisms without cell walls, such 
as Mycoplasma spp. or parasites; a possible paradoxi­
cal increase in exogenous background contamination 
by use of additional reagents101; and the inability to 
detect free nucleic acid from dead organisms that are 
lysed in vivo by human host immune cells or antibiotic 
treatment. The importance of retaining the ability for 
cell­ free DNA detection from culture­ negative samples 
from dead organisms is also why incorporation of a 
propidium monoazide treatment step to select for DNA 
from live organisms may not be clinically useful as an 
enrichment method for mNGS102. In general, both the 
differential lysis and propidium monoazide approaches 
would also be cumbersome to implement in a highly 
reproducible fashion, which is needed for clinical 
laboratory validation.
To some extent, the human host background limi­
tation may be overcome with brute force, made possi­
ble by the increasing capacities of available sequencers. 
For instance, an astrovirus was detected in a child with 
encephalitis by ultradeep sequencing of brain tissue, 
yielding only 1,612 reads out of ~134 million (0.0012%) 
sequences103. Yet another approach to improve sensitiv­
ity is to leverage a hybrid method for enrichment, such 
as metagenomic sequencing with spiked primers46. 
Combining targeted with untargeted sequencing, the 
method uses variably sized panels (100–10,000) of short 
primers that are added (‘spiked’) into reaction mixtures 
to enrich for specific target organisms while retaining 
the breadth of metagenomic sequencing for off­ target 
organisms. When spiked at the reverse transcription 
step, a panel of ZIKV­ specific primers was found to 
increase the number of ZIKV reads by more than ten­
fold without appreciably decreasing broad metagenomic 
sensitivity for other pathogens, enabling whole­ genome 
viral sequencing to characterize ZIKV spread from 
Brazil into Central America and Mexico46.
Laboratory workflow considerations
The complexity of mNGS analysis requires highly 
trained personnel and extreme care in sample handling 
to avoid errors and cross­ contamination. Even miniscule 
amounts of exogenous DNA or RNA introduced during 
sample collection, aliquoting, nucleic acid extraction, 
library preparation or pooling can yield a detectable 
signal from contaminating reads. In addition, labora­
tory surfaces, consumables and reagents are not DNA 
free. A database of background microorganisms com­
monly detected in mNGS data and arising from nor­
mal flora or laboratory contamination101,104 typically 
needs to be maintained for accurate mNGS analyses. 
Microorganisms on this list are either not reported or 
will require higher thresholds for reporting if they are 
clinically significant organisms.
Box 1 | Where is the signal — cellular or cell- free DNA?
metagenomic sequencing for clinical diagnostic purposes typically uses a shotgun 
approach by sequencing all of the DNA and/or RNA in a clinical sample. Clinical 
samples can vary significantly in their cellularity, ranging from cell- free fluids (that is, 
plasma, bronchoalveolar lavage fluid or centrifuged cerebrospinal fluid) to tissues. 
In the next- generation sequencing (NGS) field, there is great interest in the use of liquid 
biopsies from cell- free DNA (cfDNA) extracted from body fluids, such as plasma, to 
identify chromosomal or other genetic mutations and thus diagnose malignancies in 
the presymptomatic phase123. Similarly, cfDNA analysis has been useful for non- invasive 
prenatal testing applications, such as for the identification of trisomy 21 (ref.124). 
One study has described the potential utility of cfDNA analysis in diagnosing invasive 
fungal infection in cases where biopsy is not possible57. Another advantage to cfDNA 
analysis is the higher sensitivity of metagenomic sequencing owing to less cellular 
background from the human host. However, limitations of cfDNA analysis may include 
decreased sensitivity for detection of predominantly intracellular pathogens, such as 
human T cell lymphotropic virus, Rickettsia spp. and Pneumocystis jirovecii, and loss of 
the ability to interrogate cellular human host responses with RNA sequencing.
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Clinical laboratory operations are characterized by 
a defined workflow with scheduled staffing levels and 
are less amenable to on­ demand testing than those of 
research laboratories. As samples are typically handled in 
batches, the frequency of batch analysis is a major deter­
minant of overall turnaround time. Unless fully auto­
mated sample­ handling systems are readily available, 
wet lab manipulations for mNGS require considerable 
hands­ on time to perform, as well as clinical staff who 
are highly trained in molecular biology procedures. 
There are ergonomic concerns with repetitive tasks 
such as pipetting, as well as potential for inadvertent 
sample mix­ up or omission of critical steps in the work­
flow. Maintaining high quality during complex mNGS 
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Fig. 3 | Challenges to routine deployment of metagenomic sequencing in the clinical setting. At each step in the 
process, multiple factors (bullet points) must be taken into account when implementing a clinical metagenomic pipeline 
for diagnosis of infections to maximize accuracy and clinical relevance. In particular, it is often useful to interpret and 
discuss the results of metagenomic next- generation-sequencing (mNGS) testing in a clinical context as part of a clinical 
microbial sequencing board, akin to a tumour board in oncology. EMR , electronic medical record.
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procedures can be stressful to staff, as slight deviations in 
sample handling can lead to major changes in the results 
generated. Separating the assay workflow into multiple 
discrete steps to be performed by rotating shifts can be 
helpful to avoid laboratory errors.
Reference standards
Well­ characterized reference standards and controls are 
needed to ensure mNGS assay quality and stability over 
time. Most available metagenomic reference materials 
are highly customized to specific applications (for exam­
ple, ZymoBIOMICS Microbial Community Standard 
for microbiome analyses and bacterial and fungal meta­
genomics105) and/or focused on a more limited spec­
trum of organisms (for example, the National Institute 
of Standards and Technology (NIST) reference materials 
for mixed microbial DNA detection, which contain only 
bacteria106). Thus, these materials may not be applicable 
to untargeted mNGS analyses.
Custom mixtures consisting of a pool of micro­
organisms (mock microbial communities) or their 
nucleic acids can be developed as external controls to 
establish limits of detection for mNGS testing. Internal 
spike- in control standards are available for other NGS 
applications such as transcriptome analysis by RNA­ 
seq, with External RNA Controls Consortium (ERCC) 
RNA standards composed of synthetic RNA oligonu­
cleotides spanning a range of nucleotide lengths and 
concentrations107. The complete set or a portion of 
the ERCC RNA standards (or their DNA equivalents) 
can be used as spike­ in internal controls to control 
for assay inhibition and to quantify titres of detected 
pathogens by standard curve analysis108. Nonetheless, 
the lack of universally accepted reference standards for 
mNGS makes it difficult to compare assay performances 
between different laboratories. There is a critical need 
for standardized reference organisms and genomic 
materials to facilitate such comparisons and to define 
optimal analysis methods.
Bioinformatics challenges
User­ friendly bioinformatics software for analysis of 
mNGS data is not currently available. Thus, customized 
bioinformatics pipelines for analysis of clinical mNGS 
data56,109–111 still require highly trained programming staff 
to develop, validate and maintain the pipeline for clinical 
use. The laboratory can either host computational serv­
ers locally or move the bioinformatics analysis and data 
storage to cloud platforms. In either case, hardware and 
software setups can be complex, and adequate measures 
must be in place to protect confidential patient sequence 
data and information, especially in the cloud environment. 
Storage requirements for sequencing data can quickly 
become quite large, and the clinical laboratory must decide 
on the quantity, location and duration of data storage.
Bioinformatics pipelines for mNGS analysis use a 
number of different algorithms, usually developed for 
the research setting and constantly updated by soft­
ware developers. As for wet lab procedures, it is usually 
neces sary to make custom modifications to the pipeline 
software and then lock down both the software and ref­
erence databases for the purposes of clinical validation112. 
A typi cal bioinformatics pipeline consists of a series of 
analysis steps from raw input FASTQ files including 
quality and low­ complexity filtering, adaptor trimming, 
human host subtraction, microorganism identification 
by alignment to reference databases, optional sequence 
assembly and taxonomic classification of individual 
reads and/or contiguous sequences (contigs) at levels 
such as family, genus and species (fIG. 4). Each step in 
the pipeline must be carefully assessed for accuracy and 
completeness of data processing, with consideration for 
propagation of errors. Sensitivity analyses should be 
performed with the inclusion of both in silico data and 
data generated from clinical samples. Customized data 
sets can be prepared to mimic input sequence data and 
expand the range of microorganisms detected through in 
silico analysis37. The use of standardized reference mate­
rials and NGS data sets is also helpful in comparative 
evaluation of different bioinformatics pipelines105.
Additionally, public databases for microbial reference 
genomes are being continuously updated, and laborato­
ries need to keep track of the exact versions used in addi­
tion to dealing with potential misannotations and other 
database errors. Larger and more complete databases 
containing publicly deposited sequences such as the 
National Center for Biotechnology Information (NCBI) 
Nucleotide database are more comprehensive but also 
contain more errors than curated, more limited data­
bases such as FDA­ ARGOS91,113 or the FDA Reference 
Viral Database (RVDB)114. A combined approach that 
incorporates annotated sequences from multiple data­
bases may enable greater confidence in the sensitivity 
and specificity of microorganism identification.
Performance validation and verification for bioinfor­
matics analysis constitute a time­ consuming endeavour 
and include analysis of control and patient data sets and 
comparisons, with orthogonal clinical testing to deter­
mine the accuracy of the final result36. Establishing 
thresholds enables separation of true­ positive matches 
from the background, and these thresholds can incor­
porate metrics such as the number of sequence reads 
aligning to the detected microorganism, normalized to 
reads per million, external no- template control samples or 
internal spike­ in material; the number of nonoverlapping 
genomic regions covered; and the read abundance in clin­
ical samples relative to negative control samples (to avoid 
reporting of contaminant organisms). Receiver–operator 
curve (ROC) analysis is a useful tool to determine opti­
mal threshold values for a training set of clinical samples 
with known results, with verification of pre­ established 
thresholds using an independent validation set36.
As in the wet lab workflow, analysis software and ref­
erence databases should ideally be locked down before 
validation and clinical use. Many laboratories maintain 
both production and up­ to­date development versions 
of the clinical reference database (for example, the NCBI 
nucleotide database is updated every 2 weeks), with the 
production database being updated at regular, prespec­
ified intervals. Standardized data sets should be used to 
verify the database after any update and to ensure that 
assay results are accurate and reproducible, as errors 
can be introduced from newly deposited sequences and 
clinical metadata.
Spike- in
In laboratory test development, 
refers to the use of a nucleic 
acid fragment or positive 
control microorganism that is 
added to a negative sample 
matrix (for example, plasma 
from blood donors) or clinical 
samples and that serves as an 
internal control for the assay.
No- template control
In PCr or sequencing reactions, 
a negative control sample in 
which the DNA or cDNA is  
left out, thus monitoring for 
contamination that could 
produce false- positive results.
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Cost considerations
Although there have been substantial cost reductions in 
the generation of sequence data, the overall per­ sample 
reagent cost for sequencing remains fairly high. Most lab­
oratories lack the robotic equipment and established 
automated protocols to multiplex large numbers 
of patient samples in a single run. Thus, the majority of 
library preparation methods for mNGS are performed 
manually and hence incur considerable staff time. The 
additional resources needed to run and maintain a 
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Fig. 4 | A typical metagenomic next- generation sequencing 
bio informatics pipeline. A next- generation sequencing (NGS) data set, 
generally in FASTQ or sequence alignment map (SAM) format, is analysed on 
a computational server, portable laptop or desktop computer or on the cloud. 
An initial preprocessing step consists of low- quality filtering, low- complexity 
filtering and adaptor trimming. Computational host subtraction is performed 
by mapping reads to the host (for example, human) genome and setting aside 
host reads for subsequent transcriptome (RNA) or genome (DNA) analysis. 
The remaining unmapped reads are directly aligned to large reference 
databases, such as the National Center for Biotechnology Information (NCBI) 
GenBank database or microbial reference sequence or genome collections, 
or are first assembled de novo into longer contiguous sequences (contigs) 
followed by alignment to reference databases. After taxonomic classification, 
in which individual reads or contigs are assigned into specific taxa (for 
example, species, genus and family), the data can be analysed and visualized 
in a number of different formats. These include coverage map and pairwise 
identity plots to determine how much of the microbial genome has been 
recovered and its similarity to reference genomes in the database; Krona 
plots to visualize taxonomic diversity in the metagenomic library ; 
phylogenetic analysis to compare assembled genes, gene regions or 
genomes to reference sequences; and heat maps to show microorganisms 
that were detected in the clinical samples. OTU, operational taxonomic unit.
NATuRe RevIews | GeNeTiCS  volume 20 | JuNe 2019 | 351
 M I C R O B I A L  G E N O M I C S
bioinformatics analysis pipeline are also considerable, 
and steps taken to ensure regulatory oversight can add 
notably to costs as well. This leads to an overall cost 
of several hundreds to thousands of dollars per sam­
ple analysed, which is higher than that for many other 
clinical tests.
Technical improvements in hardware are needed 
for mNGS sample processing to increase throughput 
and to reduce costs. As NGS procedures become more 
standardized, there has been a drive towards increasing 
automation with the use of liquid­ handling biorobots115. 
Typically, two biorobots are needed for clinical mNGS 
for both the pre­ amplification and post­ amplification 
steps to avoid PCR amplicon cross­ contamination. 
Increased multiplexing is also possible with the greatly 
enhanced output from the latest generation of sequenc­
ers, such as the Illumina NovaSeq instruments. However, 
a potential limitation with running larger numbers of 
samples per run is longer overall turnaround times for 
clinical use owing to the requirement for batch pro­
cessing as well as sample workflow and computational 
analysis considerations. Additionally, high­ throughput 
processing of clinical samples for NGS may only be 
possible in reference laboratories. The development of 
microfluidic devices for NGS sample library preparation, 
such as VolTRAX116, could eventually enable clinicians 
to use mNGS more widely in hospital laboratories or 
point- of- care settings.
Regulatory considerations
Clinical laboratories are highly regulated, and general 
laboratory and testing requirements apply to all mole­
cular diagnostic assays reported for patient care90. 
Quality control is paramount, and methods must be 
developed to ensure analytic accuracy throughout the 
assay workflow. Important quality control steps can 
include initial sample quality checks, library param­
eters (concentration and size distribution), sequence 
data generation (cluster density and Q- score), recovery of 
internal controls and performance of external controls. 
Validation data generated during assay development and 
implementation should be recorded and made availa­
ble to laboratory inspectors (for laboratory­ developed 
tests) or submitted to regulatory agencies, such as the 
FDA in the USA or the European Medicines Agency 
(EMA) in Europe, for approval.
Ongoing monitoring is particularly important for 
mNGS assays to verify acceptable performance over 
time and to investigate atypical findings36. Monitoring is 
accomplished using sample internal controls, intra­ run 
control samples, swipe tests for contamination and perio­
dic proficiency testing. Unexpected or unusual results are 
further investigated by reviewing patients’ clinical charts 
or by confirmatory laboratory testing using orthogonal 
methods. Identification of microorganisms that have 
not been identified before in the laboratory should be 
independently confirmed, usually through clinical ref­
erence or public health laboratory testing. Atypical or 
novel organisms should be assessed for their clinical 
significance, and these findings should be reported and 
discussed with health­ care providers, with consideration 
for their potential pathogenicity and for further testing 
and treatment options. Clinical microbial sequencing 
boards, modelled after tumour boards in oncology, can 
be convened via real­ time teleconferencing to discuss 
mNGS results with treatment providers in clinical con­
text (fIG. 3). Detection of microorganisms with public 
health implications such as Sin Nombre hantavirus or 
Ebola virus should be reported, as appropriate, to the 
relevant public health agencies.
Conclusions and future perspectives
Technological advancements in library preparation 
methods, sequence generation and computational bio­
informatics are enabling quicker and more comprehen­
sive metagenomic analyses at lower cost. Sequencing 
technologies and their applications continue to evolve. 
Real­ time sequencing in particular may be a game­ 
changing technology for point­ of­care applications in 
clinical medicine and public health, as laboratories have 
begun to apply these tools to diagnose atypical infec­
tions and track pathogen outbreaks, as demonstrated by 
the recent deployment of real­ time nanopore sequencing 
for remote epidemiological surveillance of Ebola44 and 
ZIKV44,45, and even for use aboard the International 
Space Station117 (box 2).
Nonetheless, formidable challenges remain when 
implementing mNGS for routine patient care. In par­
ticular, sensitivity for pathogen detection is decreased 
in clinical samples with a high nucleic acid background 
or with exceedingly low pathogen titres; this concern is 
Box 2 | Nanopore sequencing
Nanopore sequencing is an emerging next- generation sequencing (NGS)  
technology that enables real- time analysis of sequencing data125. As such, it is 
particularly applicable to metagenomic NGS (mNGS) approaches because time is  
of the essence when treating patients with acute infectious diseases. To date, the 
only commercially available instruments for nanopore sequencing are from Oxford 
Nanopore Technologies and include the MinION (1 flow cell), GridION (5 flow  
cell capacity) and PromethIoN (48 flow cell capacity). In a published research 
study126, mNGS- based detection of Ebola and chikungunya virus infections on  
a nanopore sequencer was possible in <10 minutes of sequencing time and in 
<6 hours of sample- to-answer turnaround time overall. Research studies have 
also demonstrated the clinical potential of nanopore sequencing in targeted 
universal 16S ribosomal RNA (rRNA) bacterial detection127, microbiome analyses128, 
whole- genome sequencing of bacteria129 and outbreak viruses44,45,47, RNA 
sequencing (RNA- seq) using standardized controls130 and diagnosis of prosthetic 
joint131 and lower respiratory infections99. Untargeted approaches such as mNGS  
or whole- transcriptome RNA- seq, however, may be limited by the lower throughput 
of nanopore sequencing relative to short- read sequencing such as with an Illumina 
instrument.
Currently, no NGS- based clinical test for pathogens has been validated on a nanopore 
sequencing platform. The clinical adoption of these devices has been limited by the 
rapid pace of improvements to the platform, which can hinder clinical validation efforts 
requiring standardized instruments and locked- down protocols, and by ongoing issues 
regarding sequencing quality and yield. Nonetheless, there is enormous potential for 
nanopore sequencing in point- of-care clinical sequencing applications, such as mNGS 
testing done at a patient’s bedside or in an emergency room, local clinic or in the 
field132. Importantly, selective sequencing of pathogen reads has been demonstrated  
on the nanopore platform by early termination of the sequencing of the human reads  
as they are identified in real time133. Although attractive for purposes of protecting 
patient privacy and confidentiality, as human reads are depleted as part of the 
sequencing run, this approach is not currently scalable owing to the limited throughput 
of the nanopore sequencer to date (up to 10 million mNGS reads per run on the MinION 
nanopore sequencer as of 2019) and the need to computationally match reads to 
reference sequences in real time.
Biorobots
The automated 
instrumentation in the clinical 
laboratory that enables parallel 
processing of many samples  
at a time.
Point- of-care
refers to diagnostic testing  
or other medical procedures 
that are done near the time 
and place of patient care  
(for example, at the bedside,  
in an emergency department 
or in a developing- world field 
laboratory).
Cluster density
on Illumina sequencing 
systems, a quality control 
metric that refers to the 
density of the clonal clusters 
that are produced, with each 
cluster corresponding to a 
single read. An optimal cluster 
density is needed to maximize 
the number and accuracy  
of reads generated from a 
sequencing run.
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only partially mitigated by increasing sequencing depth 
per sample as costs continue to drop. As a comprehen­
sive direct detection method, mNGS may eventually 
replace culture, antigen detection and PCR methods in 
clinical microbiology, but indirect approaches such as 
viral serological testing will continue to play a key part in 
the diagnostic work­ up for infections27, and functional 
assays such as culture and phenotypic susceptibility test­
ing will likely always be useful for research studies. In 
summary, while current limitations suggest that mNGS 
is unlikely to replace conventional diagnostics in the 
short term, it can be a complementary, and perhaps 
essential, test in certain clinical situations.
Although the use of mNGS for informing clinical 
care has been demonstrated in multiple case reports and 
small case series118, nearly all studies have been retro­
spective, and clinical utility has yet to be established in a 
large­ scale prospective clinical trial. Prospective clinical 
studies will be critical to understand when to perform 
mNGS and how the diagnostic yield compares with that 
of other methods. For example, the mNGS transcrip­
tomic approach might enable effective treatment triage, 
whereby antimicrobials are only needed for patients 
showing an ‘infectious profile’ of gene expression and 
those with a ‘non­ infectious profile’ can be treated for 
other causes. In particular, prospective clinical trial and 
economic data showing the cost­ effectiveness of these 
relatively expensive tests in improving patient outcomes 
are needed to justify their use. These data will also sup­
port a pathway towards regulatory approval and clini­
cal reimbursement. High­ quality evidence that clinical 
metagenomic assays are effective in guiding patient 
management will require protocols that minimize 
potential assay and patient selection bias and compare 
relevant health outcomes using data sets generated from 
large patient cohorts119,120.
We predict that, over the next 5 years, prospective 
clinical trial data evaluating the clinical utility and cost­ 
effectiveness of mNGS will become available; overall 
costs and turnaround time for mNGS will continue to 
drop; other aspects of mNGS beyond mere identifica­
tion, such as incorporation of human host response and 
microbiome data, will prove clinically useful; robotic 
sample handling and microfluidic devices will be devel­
oped for push­ button operation; computational analysis 
platforms will be more widely available, both locally and 
on the cloud, obviating the need for dedicated bioinfor­
matics expertise; and at least a few mNGS­ based diag­
nostic assays for infectious diseases will attain regulatory 
approval with clinical reimbursement. We will witness 
the widespread democratization of mNGS as genomic 
analyses become widely accessible not only to physicians 
and researchers but also to patients and the public via 
crowdsourcing initiatives121,122. Furthermore, in a world 
with constantly emerging pathogens, we envisage that 
mNGS­ based testing will have a pivotal role in monitor­
ing and tracking new disease outbreaks. As surveillance 
networks and rapid diagnostic platforms such as nano­
pore sequencing are deployed globally, it will be possi­
ble to detect and contain infectious outbreaks at a much 
earlier stage, saving lives and lowering costs. In the near 
future, mNGS will not be a luxury but a necessity in the 
clinician’s armamentarium as we engage in the perpetual 
fight against infectious diseases.
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A sequencing method in which 
DNA or rNA molecules are 
transported through miniature 
pores by electrophoresis. 
Sequencing reads are 
generated by measurement  
of transient changes in ionic 
current as the molecule passes 
through the pore.
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